新型口服头孢菌素BAY v 3522的体外活性
In vitro activity of BAY v 3522, a new oral cephalosporin.
作者信息
Fass R J
机构信息
Department of Internal Medicine, Ohio State University College of Medicine, Columbus 43210.
出版信息
Antimicrob Agents Chemother. 1990 Sep;34(9):1855-7. doi: 10.1128/AAC.34.9.1855.
The in vitro activity of BAY v 3522 was compared with the activities of cephalexin, cefaclor, cefuroxime, cefixime, and amoxicillin-clavulanate. MICs (in micrograms/ml) of BAY v 3522 were as follows: Staphylococcus spp. (except for oxacillin-resistant strains), 0.13 to 1; Streptococcus spp. (except for some viridans group streptococci), less than or equal to 0.015 to 0.25; Enterococcus faecalis, 2 to 8; other enterococci, 0.5 to greater than 32; beta-lactamase-negative Haemophilus influenzae and Branhamella catarrhalis, 0.13 to 1; beta-lactamase-positive H. influenzae and B. catarrhalis, 0.5 to 4; Pasteurella multocida, 0.06 to 0.25; and members of the family Enterobacteriaceae, 0.5 to greater than 32. Among the cephalosporins, BAY v 3522 was the most active against gram-positive cocci and cefixime was the most active against gram-negative bacilli; BAY v 3522 was similar in activity to amoxicillin-clavulanate against most species.
将BAY v 3522的体外活性与头孢氨苄、头孢克洛、头孢呋辛、头孢克肟和阿莫西林-克拉维酸的活性进行了比较。BAY v 3522的最低抑菌浓度（以微克/毫升计）如下：葡萄球菌属（耐苯唑西林菌株除外），0.13至1；链球菌属（部分草绿色链球菌除外），小于或等于0.015至0.25；粪肠球菌，2至8；其他肠球菌，0.5至大于32；β-内酰胺酶阴性的流感嗜血杆菌和卡他莫拉菌，0.13至1；β-内酰胺酶阳性的流感嗜血杆菌和卡他莫拉菌，0.5至4；多杀巴斯德菌，0.06至0.25；以及肠杆菌科成员，0.5至大于32。在头孢菌素中，BAY v 3522对革兰氏阳性球菌活性最强，头孢克肟对革兰氏阴性杆菌活性最强；BAY v 3522对大多数菌种的活性与阿莫西林-克拉维酸相似。
Zotero 插件